Streetbeat News

Regulatory

EBS

Emergent Biosolutions (EBS) announced that during their quarterly review for the quarter ended September 30, 2023, they discovered an overstatement of their net state deferred tax liability as of December 31, 2022. Consequently, the financial statements included in the original Form 10-K should no longer be relied upon, indicating a need for restatement.

Portfolio Pulse from Charles Gross

December 11, 2023 | 12:26 pm

TNXP

Tonix Pharmaceuticals is scheduled to present at The National Academies Committee meeting on the current state of research, development, and stockpiling of smallpox medical countermeasures. This presentation could provide insights into the company's involvement in smallpox countermeasures and potentially affect its visibility and credibility in the biopharmaceutical sector.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:04 pm

GOLD

The US Bureau of Land Management has approved Nevada Gold Mines' Plan of Operations for the new Goldrush Underground Mine. The mine, expected to start production in 2024, is forecasted to produce 130,000 ounces of gold in its first year and reach approximately 400,000 ounces annually by 2028.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:03 pm

ORTX

Orchard Therapeutics (NASDAQ:ORTX) has received approval from Swissmedic for Libmeldy, a gene therapy for early-onset metachromatic leukodystrophy (MLD).

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:02 pm

MRK

Merck Animal Health, a division of Merck & Co., received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) for an injectable formulation of BRAVECTO (Fluralaner) for dogs. The CVMP recommends approval for the treatment of fleas and ticks in dogs for 12 months. The recommendation is pending adoption by the European Commission, which would allow the product to be used by veterinarians for dogs and puppies six months and older.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:47 am

PNM

The Hearing Examiners have issued recommended decisions regarding the Public Service Company of New Mexico's (PNM) application for a change in customer base rates in 2024 and its application for 12 megawatts of distribution battery storage. PNM, a subsidiary of PNM Resources, is awaiting final decisions on these applications which could impact its revenue and investment in energy storage infrastructure.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:36 am

GSK

The European Commission has granted full approval to GSK's Jemperli (dostarlimab) in combination with chemotherapy for certain advanced or recurrent endometrial cancers. Additionally, Jemperli's conditional approval as a monotherapy for the same type of cancer, after prior platinum-containing regimen treatment, has been converted to full approval.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:26 am

FXI

NVDA

SPY

TCEHY

Chinese companies, including Tencent, are promoting their AI chips as alternatives to Nvidia's products in response to U.S. export restrictions. These restrictions have limited China's access to Nvidia's advanced chips, prompting local firms to accelerate their own AI chip development. Sources familiar with the matter have indicated that these companies are seizing the opportunity to fill the gap left by Nvidia in the Chinese market.

Portfolio Pulse from Charles Gross

December 11, 2023 | 10:28 am

NVDA

Nvidia Corp. (NASDAQ:NVDA) is planning to expand its presence in Vietnam by deepening partnerships with top tech firms such as Viettel, FPT, Vingroup, and VNG. CEO Jensen Huang announced the expansion during his first visit to Hanoi, highlighting that Nvidia already has millions of clients in Vietnam. The company has invested $250 million in Vietnam, focusing on AI deployment in various industries. The Vietnamese government is incentivizing investments in the semiconductor and AI industries, and Nvidia's move is seen as a diversification strategy amid the U.S. chip ban affecting sales in China.

Portfolio Pulse from Shanthi Rexaline

December 11, 2023 | 9:02 am

BTCUSD

Bitcoin (BTC) experienced a sharp decline, dipping below $42,000, with a significant drop in social dominance and engagement according to LunarCrush data. Despite this, Bitcoin has seen over 150% growth since the year's start, partly due to expectations of SEC approval for Bitcoin ETFs and potential Federal Reserve interest rate adjustments. BTC was trading at $42,149, down 4.21% over the last 24 hours.

Portfolio Pulse from Mehab Qureshi

December 11, 2023 | 8:33 am